Primary endpoint tissue survival. Medical search. Frequent questions

Secondary endpoints included progression-free survival (PFS) and overall survival (OS). (jefferson.edu)
secondary endpoints included acute and late toxicity, the proportion of adaptive fractions used, patient-reported outcomes, disease control, disease progression, and overall survival. (medpagetoday.com)
secondary endpoints included the duration of response, progression-free survival, and safety. (esmo.org)
Secondary endpoints included overall survival and the overall response rate. (medscape.com)
The key secondary endpoint was progression free survival and the other secondary endpoints included overall survival, safety and relationship between PD-L1 status and anti-tumour activity. (ecancer.org)

The primary end point was the objective response rate (ORR), and secondary end points were toxicity, progression-free survival, and overall survival. (bmj.com)
Secondary end points included progression-free survival, objective response rate, duration of response, and safety. (cancernetwork.com)
We are also encouraged by the substantial reductions in tumor volume and T2 hyperintensity seen in the DeFi study, which are consistent with the significant improvements in progression-free survival and objective response rate previously reported, and further elaborate on the activity profile of nirogacestat in desmoid tumors. (tmcnet.com)
The primary endpoint was safety, with secondary objectives including progression-free survival (PFS), overall survival (OS), and objective response rate (ORR). (internalmedicineiowa.org)
For secondary objective, response rate was 64.5%, median PFS was 8.2 months [95% CI: 5.9-8.6] and overall survival was not reached in MSS patients. (omicsdi.org)
gene signature was prospectively evaluated as a potential predictive biomarker in second- and third-line patients receiving the combination (arm E). The coprimary endpoints were objective response rate and progression-free survival (PFS) rate at 6 months. (omicsdi.org)
The trial found that the addition of pembrolizumab, a PD-1 antibody, to standard first-line chemotherapy for treatment-naive advanced NSCLC achieved significantly longer progression free survival, a great objective response rate, and a well tolerated toxicity profile. (ecancer.org)

Our analyses of blood, tissue, and/or fluids may lead to improved diagnosis and treatment of cancer by the identification of markers that predict clinical outcome, markers that predict response to specific therapies, and the identification of targets for new therapies. (stanford.edu)
While retrospective analyses have shown that oral sirolimus can improve survival in BOS patients, systemic toxicities have limited its widespread adoption. (itbusinessnet.com)
Blood samples were assessed for vaccine-induced T-cell responses, and tumor tissues were collected for translational analyses. (internalmedicineiowa.org)
Secondary and exploratory endpoints include the overall response rate based on Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria and volumetric analyses, event free survival, safety, functional outcomes, and quality of life measures. (dayonebio.com)

Exploratory endpoints included the association of baseline programmed death-ligand 1 (PD-L1) expression as well as on-treatment changes in immune bias with treatment outcomes. (jefferson.edu)
Changes from baseline in pain severity were compared between treatment arms at Cycle 10 per the prespecified exploratory endpoints. (tmcnet.com)
Baseline tumor tissue was analyzed for EGFR by fluorescence in situ hybridization (FISH). (psu.edu)
EGFR gene copy number on baseline tumor tissues, analyzed by FISH, was not predictive of efficacy outcomes. (psu.edu)
Primary endpoint of this study is the concordance of EGFR mutation status between tissue and plasma at baseline. (iaslc.org)
The company says the drug met its primary endpoint, defined as change from baseline in the Motor Function Measure 32 (MFM-32) scale after one year of treatment, compared to placebo. (pharmatimes.com)

In this patient population, ridaforolimus improved progression-free survival (PFS) compared to placebo, the primary endpoint of the study. (wikipedia.org)
Based on 552 progression-free survival (PFS) events in 711 patients, (ridaforolimus (N=347), placebo (N=364) determined by an independent radiological review committee, the study achieved its primary endpoint of improvement in PFS, with a statistically significant (p=0.0001) 28 percent reduction in the risk of progression or death observed in those treated with ridaforolimus compared to placebo (hazard ratio=0.72). (wikipedia.org)
A statistically significant improvement in radiological progression-free survival was observed for olaparib with abiraterone compared to placebo with abiraterone in the intent-to-treat (ITT) population. (gtviral.com)
The study met its primary endpoint showing statistical significance in progression-free survival (PFS) for patients treated with zolbetuximab plus mFOLFOX6 compared to placebo plus mFOLFOX6. (labiotech.eu)
In addition, the Astellas' study met a secondary endpoint, overall survival (OS), showing statistical significance for patients treated with zolbetuximab plus mFOLFOX6 compared to placebo plus mFOLFOX6. (labiotech.eu)

formerly known as deforolimus) is an investigational targeted and small-molecule inhibitor of the protein mTOR, a protein that acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival, integrating signals from proteins, such as PI3K, AKT and PTEN known to be important to malignancy. (wikipedia.org)
The primary endpoint of the study was progression free survival (PFS). (biospace.com)
Secondary end points include safety (toxicities and AEs) assessed as per Common Terminology Criteria for Adverse Events Version 5.0, progression-free survival, overall survival, and ORR as determined by immune-based RECIST criteria. (onclive.com)
Talazoparib plus enzalutamide resulted in clinically meaningful and statistically significant improvement in radiographic progression-free survival (rPFS). (esmo.org)
The inhibition of two immune checkpoints, LAG-3 using relatlimab and PD-1, improved progression-free survival (PFS) to a greater extent than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. (biomedcentral.com)
The primary endpoint was 6-month progression-free survival (PFS6). (healthpartners.com)
The first one was the non-inferiority in terms of progression free survival of the experimental arm versus the standard arm. (ecancer.org)
In fact, for the de-escalation arm with cetuximab alone, the experimental arm achieves an interesting performance in progression free survival with 10 months in median progression free survival. (ecancer.org)
The median overall survival was 19.4 months and the median progression-free survival 9.3 months. (psu.edu)
Secondary endpoints are overall response rate, progression-free survival and safety. (iaslc.org)
The primary efficacy outcome measure was investigator-assessed radiological progression-free survival according to Response Evaluation Criteria in Solid Tumors version 1.1 for soft tissue lesions and Prostate Cancer Working Group criteria for bone lesions. (gtviral.com)
An exploratory subgroup analysis in 85 patients with BRCA extension -mutated disease (11% of the ITT population) demonstrated a median radiological progression-free survival that was not achieved in the olaparib with abiraterone arm compared to 8 months (95% confidence interval [CI] = 615 months) for those receiving placebo with abiraterone (hazard ratio [HR] = 0.24, 95% CI = 0.120.45). (gtviral.com)
In 711 patients (89% of the ITT population) without a BRCA extension mutation, the hazard ratio for radiological progression-free survival was 0.77 (95% CI = 0.630,96) and the hazard ratio for overall survival was 0.92 (95% CI = 0.741,14), suggesting that the improvement in radiological progression-free survival observed in the ITT population was primarily attributable to patients with BRCA extension - mutated disease. (gtviral.com)
p=0.0046), and also significantly improved progression-free survival. (biocentury.com)
The overall response rate was impressive 57%, with a median progression-free survival of 11 months, values suggesting that the efficacy of idelalisib is similar or superior to those of other active treatment options in relapsed or refractory indolent non-Hodgkin's lymphoma. (esmo.org)
The median time to a response was 1.9 months, the median duration of response was 12.5 months, and the median progression-free survival was 11 months. (esmo.org)
Secondary endpoints include progression-free survival (PFS) by independent review committee (IRC) per RANO-LGG, duration of response (DOR) assessed by IRC per RANO-LGG, and overall survival. (dayonebio.com)
Secondary and exploratory endpoints include safety, duration of response, progression-free survival, and time to response. (dayonebio.com)
The agent reduced the risk of recurrence, progression, or death by 55% vs transurethral resection of bladder tumor (TURBT) alone in the ATLAS trial, and met its primary end point of disease-free survival (DFS). (cancernetwork.com)
1 The Checkmate 227 study was amended to add a co-primary end point of progression-free survival (PFS) by tissue TMB, with the TMB cutoff prespecified as 10 mutations per megabase (mut/Mb), based on data from the phase 2 CheckMate 568 study ( NCT02659059 ). (jamanetwork.com)
Progression free survival is also significantly improved for the combination with a hazard ratio of 0.53 and a p-value of 0.0102. (ecancer.org)
At six months 77% are free from progression in the pembro combination compared to 63% in the control group and the median progression free survival for the pembro chemo combination is over a year, it's 13 months compared to 8.9 months for chemotherapy alone. (ecancer.org)

In a dermal toxicity study (see section 7.2.3) with rabbit skin it was shown, in addition, that the toxicity of MCA is not caused by a surplus of H+ ions and that the inﬂuence of pH appeared to be secondary, because its direct reaction to biomolecules was the primary cause of cytotoxicity. (europa.eu)

It has had promising results in a clinical trial for advanced soft tissue and bone sarcoma. (wikipedia.org)
On June 6, 2011, Ariad and Merck announced detailed results from the largest randomized study ever in the soft tissue and bone sarcoma population, the Phase III SUCCEED clinical trial. (wikipedia.org)
SUCCEED evaluated oral ridaforolimus, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy. (wikipedia.org)
The SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus) trial was a randomized (1:1), placebo-controlled, double-blind study of oral ridaforolimus administered at 40 mg/day (five of seven days per week) in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy. (wikipedia.org)
Dr. Agarwal highlights the unique inclusion criteria of the study, which required patients to have progressive measurable disease in soft tissue metastasis. (urotoday.com)
5 individuals developed in-field soft tissue ulceration during consolidation immunotherapy, resulting in one fatality. (jefferson.edu)
Early changes in circulating biomarkers appear able to predict treatment outcomes as well as ensuing in-field soft tissue ulceration. (jefferson.edu)
As the current literature provides few information on reconstruction-technique-dependent outcomes following surgery for bone and soft tissue neoplasms involving the proximal tibia, the current multicentre retrospective study may allow to draw further conclusions on how to best approach tumours at this specific anatomical location. (emsos.org)
Then, cone-beam computed tomography (CBCT) and volumetric soft-tissue imaging are used to make a 3-dimensional image that can be obtained right before treatment. (medpagetoday.com)

Patients were prospectively assessed for HRR gene alterations in tumour tissue and randomly assigned (1:1) to talazoparib 0.5 mg or placebo, plus enzalutamide 160 mg, administered orally once daily. (esmo.org)

The primary endpoint of the study was the percentage of patients who achieve hematologic complete response. (biospace.com)
The results from the primary analysis of the all-comers population in the phase III TALAPRO-2 study support the consideration of the novel combination of talazoparib plus enzalutamide versus a standard of care, enzalutamide, as a first-line treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC). (esmo.org)
The NGS analysis of tissue sample or liquid biopsy are ongoing in our study and we hope to present these results in our next meeting. (ecancer.org)
No study aims to evaluate the impact of rt-PA locking in long-term Hemodialysis (HD) uncuffed catheters survival. (druglib.com)
In the Phase 2 monotherapy portion (sub-study 1), patients will be enrolled either into a melanoma cohort or a "tissue agnostic" cohort. (dayonebio.com)
2 , 3 Both studies used the FoundationOne CDx assay for tumor TMB testing on archival/fresh tumor tissue collected prior to study enrollment, with valid TMB data available for only 57.7% and 41.1% of randomized patients from the CheckMate 227 and MYSTIC studies, respectively. (jamanetwork.com)
This study aimed to estimate the probability of survival in patients with bladder cancer in Jordan and identify fac- tors associated with survival. (who.int)

Survival three main types of bladder cancer: transitional cell car- rates varies significantly among age groups. (who.int)
5-year survival decreased significantly from 90.8% in (1) . (who.int)

The primary endpoint was safety of definitive RIT. (jefferson.edu)
The second co-primary endpoint was a better profile of safety in terms of lower incidence of grades or 4 adverse events for the experimental arm than the standard arm. (ecancer.org)
Safety was primary objective of phase IB and no safety issue was observed. (omicsdi.org)

Ewing-like sarcomas of bone and soft tissues: entities, strategies and outcomes. (emsos.org)
Intravesical UGN-102 (mitomycin) improved clinical outcomes among patients with low-grade, intermediate-risk, non-muscle invasive bladder cancer (NMIBC), thereby meeting the primary end points of the phase 3 ATLAS (NCT04688931) and ENVISION trials (NCT05243550), according to a press release from UroGen Pharma. (cancernetwork.com)

The study's primary end point is the overall response rate (ORR) as determined by RECIST 1.1 criteria. (onclive.com)
The primary endpoint will be overall response rate (ORR), defined as the proportion of patients with best overall confirmed response rate based upon Response Assessment for Neuro-Oncology (RANO) criteria. (dayonebio.com)
The primary endpoint will be overall response rate (ORR) based upon Response Assessment for Neuro-Oncology (RANO) criteria. (dayonebio.com)
The primary endpoint will be overall response rate (ORR) as assessed by RECIST version 1.1 criteria. (dayonebio.com)
The primary endpoint was overall response rate, as evaluated by a blinded independent central review. (ecancer.org)

We are studying components of blood, tumor tissue, normal tissue, and other fluids, such as urine, cerebrospinal fluid, abdominal or chest fluid in patients with cancer. (stanford.edu)
We tested various specimens (blood, cerebrospinal fluid, intraocular fluid, serum, and tissues) from the organ donor and recipients by serology, RT-PCR, immunohistochemistry, metagenomic next-generation sequencing, and host gene expression, and conducted a traceback of blood transfusions received by the organ donor. (cdc.gov)

Correlative tissue analysis demonstrated an association between pSRC/LYN signaling in patient tumors and outcome. (healthpartners.com)
Further endpoints include outcome stratification according to parameters as tumour site and tumour stage at diagnosis, as well as the identification of risk factors independently associated with worse survival. (emsos.org)

Amyloidosis is a disease that occurs when amyloid proteins, which are abnormal proteins, accumulate in tissues and organs. (biospace.com)
When the amyloid proteins cluster together, they form deposits that damage the tissues and organs. (biospace.com)
Gastric cancer is often diagnosed in the advanced or metastatic stage, or once it has spread from the tumor's origin to other body tissues or organs. (labiotech.eu)
Because early-stage gastric cancer symptoms frequently overlap with more common stomach-related conditions, gastric cancer is often diagnosed in the advanced or metastatic stage, or once it has spread from the tumor's origin to other body tissues or organs. (labiotech.eu)

Primary chemoprevention is directed at patients with premalignant lesions (mucosal keratosis with atypia and erythroplakia). (medscape.com)

For the 41 patients with paired samples obtained after acquisition of EGFR-TKI resistance, the concordance for mutation detection by ddPCR in plasma compared with tumor tissue or malignant fluid specimens was 78.0% for TKI-sensitizing mutations and 65.9% for T790M. (iaslc.org)

This case series reports five appropriate clinical scenarios that highlight the utility of a GEP-based assay to effectively provide a molecular tumor classification to identify NEN subtypes and tumor primary site of origin. (bvsalud.org)

Plasma specimens from all subjects as well as tumor tissue or malignant pleural effusion or ascites from 41 patients were collected after the development of EGFR-TKI resistance. (iaslc.org)

The primary endpoint was the durable response rate (DRR), defined as the rate of complete response plus partial response continuously lasting ≥ 6 months and beginning within the first 12 months. (medscape.com)

MATERIALS AND METHODS: Sections from tissue microarray (TMA) including 13 archival metastatic primary and 18 non-metastatic primary pancreatic endocrine carcinomas/tumors (MP-PECAs/NMP-PETs) were stained with a monoclonal anti-p21WAFI,CIP primary antibody. (bvsalud.org)
Methods Immunohistochemistry was performed on patient derived xenograft (PDX) brains and tissue microarrays of 16 patient matched primary/recurrent GBMs as well as 23 normal organ tissues. (bmj.com)
2010). Polycyclic aromatic hydrocarbon exposure standard mammogram form and the interactive kinase in response to estradiol in breast cancer in oesophageal tissue and risk of oesophageal threshold measurement methods. (who.int)

IL-15 is considered superior to IL-2 for cancer immunotherapy due to its strong bioactivity in improving CD8 + T and natural killer (NK) cell survival, proliferation and cytotoxic function ( 8 ). (frontiersin.org)

Additional eligibility criteria included having a life expectancy longer than 3 months, adequate organ function, and providing archival tumor tissue samples. (cancernetwork.com)
Recent infection with yellow fever virus was confirmed in all four organ recipients by identification of yellow fever virus RNA consistent with the 17D vaccine strain in brain tissue from one recipient and seroconversion after transplantation in three recipients. (cdc.gov)

Feng X, Zhang L, Ke S, Liu T, Hao L, Zhao P, Tu W, & Cang S. High expression of GPNMB indicates an unfavorable prognosis in glioma: Combination of data from the GEO and CGGA databases and validation in tissue microarray. (bmj.com)

The primary aim is to assess mid- to long-term survival of Ewing-like sarcoma patients (both soft tissues and bones). (emsos.org)
Intratumoral GET with plasmid IL-15/IL-15Rα leads to a long-term survival benefit in 4T1 mammary carcinoma model. (frontiersin.org)

More and more interesting, in the overall survival results the experimental arm achieved a median overall survival of over [inaudible] months. (ecancer.org)

Given the fact that the proximal tibia is one of the most frequently affected locations for primary bone tumours, sufficient reconstruction of the adjacent knee joint is of importance. (emsos.org)
Chondrosarcoma is one of the most frequent primary bone sarcoma. (emsos.org)
Primary leiomyosarcoma of bone (LMSoB) is a rare subtype of bone sarcomas, accounting for less than 0.7% of all malignant bone tumours. (emsos.org)

Eliminating GPNMB in cell lines decreased proliferation (P≤0.001) and prolonged survival times in all mouse models (P≤0.01) indicating its functional relevance. (bmj.com)
CAR-T cytotoxicity and activation was observed in vitro and in vivo resulting in decreased tumor burden (P≤0.001) and increased survival times (P≤0.001). (bmj.com)

The benefit of dual checkpoint blockade with anti CTLA-4 and anti PD-1 inhibitor over monotherapy with a CTLA-4 inhibitor has been shown, with durable disease control and improved overall survival (OS). (biomedcentral.com)

The median overall survival (OS) was 17.5 months in cohort A compared with 6.7 months in cohort B and 4 months in cohort C. (ccanewsonline.com)

In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median and 2-year survival for patients with glioblastoma treated with concomitant and adjuvant temozolomide and radiotherapy. (nih.gov)
For the ERMES trial we had two co-primary endpoints. (ecancer.org)
The ERMES trial did not meet the first primary endpoint but we have some interesting results that we can bring into our clinical practice. (ecancer.org)
The approval of Advanced Accelerator Applications (AAA)'s Pluvicto is based on the alternate primary endpoint results from the randomised, open-label, international, multi-centre, Phase III VISION trial, where patients with progressive PSMA positive mCRPC treated with at least one AR pathway inhibitor and one or two taxane regimens. (europeanpharmaceuticalreview.com)
Vigil is the first cellular immunotherapy to demonstrate survival benefits in a randomized controlled trial of patients with solid tumors. (globenewswire.com)
I am excited by the potential for a new treatment option to help patients with advanced-stage gastric cancer or GEJ cancer," said Kohei Shitara, primary investigator for the SPOTLIGHT trial and chief, Department of Gastrointestinal Oncology, the National Cancer Center Hospital East in Kashiwa , Japan. (labiotech.eu)
Shares of ImmunoGen Inc. (NASDAQ:IMGN) rose $7.06 (136%) to $12.26 Wednesday, lifting its market cap to $2.8 billion, after the company reported that Elahere mirvetuximab soravtansine-gynx showed a survival benefit in the Phase III MIRASOL trial to treat ovarian cancer, meeting its primary endpoint. (biocentury.com)
The single-arm, multinational ENVISION trial includes an enrolled population of 240 patients with low-grade, intermediate-risk disease from 56 sites, and is assessing the agent as a primary chemoablative therapy. (cancernetwork.com)
To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. (who.int)

The ITT analysis and overall survival results are suggestive for a strategy of de-escalation treatment with only cetuximab. (ecancer.org)

Background Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. (bmj.com)

CRISPR/Cas9 was used to eliminate expression in GBM lines to measure proliferation and mouse survival times. (bmj.com)

The primary end point is the CR rate at 3 months after the first dose. (cancernetwork.com)

Results will inform the development and implementation of pediatric obesity clinical trials in primary care settings, as well as the creation of a research practice network. (umc.edu)

In Sweden, the 5-year relative survival for almost 90% of all cases. (who.int)

Her survey will assess interest in receiving evidence based pediatric obesity prevention and treatment in primary care settings, as well as perceived barriers and facilitators to participating in pediatric obesity focused clinical trials research. (umc.edu)
Pediatric primary care providers (n = 36) will participate in focus groups to examine knowledge of pediatric overweight and obesity expert prevention and treatment recommendations, as well as needs and interest for an obesity specific practice network and pediatric obesity clinical trials research. (umc.edu)
UGN-102, in development as the potential first non-surgical therapy for LG-IR-NMIBC, met primary endpoints in both phase 3 ATLAS and ENVISION clinical trials. (cancernetwork.com)
However, ACE inhibitors, ARBs, or aldosterone antagonists (mineralocorticoid receptor antagonists) are often used to treat HFpEF and/or associated comorbidities (such as hypertension and renal dysfunction), although survival benefit has not been demonstrated in clinical trials and, therefore, are not considered a standard of care. (msdmanuals.com)

I'm a board certified neuro-oncologist who treats both primary brain tumors as well as metastatic disease to the brain and nervous system. (stanford.edu)
Ultimately a CD133+ population was observed in residual tumors of GPNMB treated mice at endpoint. (bmj.com)

Blood, tissue, and fecal samples were collected at multiple points for correlative studies to evaluate immunity biomarkers. (bmj.com)
The correlative studies will analyze blood- and tissue-based biomarkers, including immune markers. (onclive.com)

BACKGROUND/AIM: Cancer of unknown primary (CUP), representing 3-5% of all newly diagnosed cancers in the United States, is a presumptive, non-definitive diagnosis rendered when a primary tumor site cannot be identified after exhaustive diagnostic evaluation, including cases of neuroendocrine neoplasms (NENs). (bvsalud.org)

2-4 Overall survival for esophageal cancer remains poor, especially for metastatic disease with a median survival of slightly over 1 year from the time of diagnosis. (onclive.com)

The primary indication for infrapopliteal bypass is critical limb ischemia (CLI) due to atherosclerotic peripheral arterial disease (PAD). (medscape.com)
no antecedent interstitial lung disease or pneumonitis requiring systemic steroids and provision of a tissue sample adequate for PD-L1 assessment. (ecancer.org)
Secondary chemoprevention is targeted at patients with cancer who, in order to prevent recurrent disease or to prevent metachronous primary diseases, have undergone potentially curative therapy. (medscape.com)
Bilateral micronodular hyperplasia (primary pigmented nodular adrenocortical disease) and macronodular hyperplasia are rare causes of Cushing syndrome. (medscape.com)
Specifically, it is a progressive, small- and medium-size arterial occluding disease, leading to tissue infarction and initially involving the skin. (medscape.com)
Some authorities suggest that the primary endothelial cell defect with secondary thrombosis leads to infarctive changes manifesting as Degos disease. (medscape.com)

2. Tissue sample collected by EUS-FNA/FNB and histopathologically diagnosed as having adenocarcinoma. (who.int)

This allows for a plan that matches the bladder target, which reduces the amount of radiation delivered to normal tissue. (medpagetoday.com)

Using a p21 immunohistochemistry (IHC) assay, we compared tumor p21 levels with conventional clinico-pathological criteria in primary pancreatic endocrine tumor subsets with and without liver metastases. (bvsalud.org)

The hazard ratio for overall survival in these patients was 0.30 (95% CI = 0.150.59). (gtviral.com)
Cox proportional hazard regression was used to identify independent factors associated with survival. (who.int)

Better survival was observed in patients with early stage and well differentiated tumours at diagnosis. (who.int)

Anatomy3

Organisms1

Diseases50

Chemicals and Drugs62

Analytical, Diagnostic and Therapeutic Techniques and Equipment91

Phenomena and Processes14

Disciplines and Occupations3

Anthropology, Education, Sociology and Social Phenomena3

Technology, Industry, Agriculture2

Humanities1

Information Science5

Health Care53

Geographicals7

Secondary endpoints included5

Objective resp7

Analyses4

Baseline6

Compared to placebo5

Progression22

Toxicity1

Soft-tissue9

Placebo1

Study7

Significantly2

Safety3

Outcomes2

Overall response rate5

Cerebrospinal fluid2

Outcome2

Organs4

Lesions1

Mutation1

Classification1

Specimens1

Response rate1

Methods3

Cell survival1

Organ2

Microarray1

Long-term survival2

Achieved a median1

Bone3

0.0012

Durable1

Cohort1

Trial9

Cetuximab1

Malignant1

Proliferation1

Months1

Results1

Relative survival1

Clinical trials4

Tumors2

Correlative2

Newly diagnosed1

Metastatic disease1

Disease6

Adenocarcinoma1

Normal tissue1

Assay1

Hazard2

Tumours1